23 July 2012 1  RV144: Clinical Development Plans IAS 2012, Washington, DC USA The views expressed are those of the presenter and should not be construed.

Slides:



Advertisements
Similar presentations
The Path Forward for HIV-1 Vaccine Development
Advertisements

Pox-Protein Public-Private Partnership (P5)
1 Workshop on the immunological basis of vaccine efficacy Vaccine and Infectious Disease Institute December 14, 2009 Ira M. Longini, Jr. Center for Statistical.
Carl W. Dieffenbach, Ph.D. Director Division of AIDS, NIAID July 2, 2013 HIV Vaccine and Future Strategies.
State of the Field Exploring 2015’s Top Ten List for the HIV Prevention Research Field Manju Chatani, Stacey Hannah, Mitchell Warren Thursday, January.
Designing and Optimizing an Adenovirus Encoded VLP Vaccine against HIV Anne-Marie Andersson PhD Student, University of Copenhagen.
Prof. Fatma Amer Medical Microbiology and Immunology, ZAGAZIG FACULTY OF Medicine, Egypt President of ISC/HWG President of ArAPUA In the Era of Direct.
HIV-VACCINES. HIV - Vaccines  Vaccine development remains priority of AIDS research   Best hope for protection against HIV infection.
What can we learn from diverse spectrum of HIV/SIV infections? Françoise BARRÉ-SINOUSSI Regulation of Retroviral Infections Unit Department of Virology.
National Vaccine Advisory Committee June 7, 2005 Pandemic Influenza Vaccine Research and Development Linda C. Lambert Chief, Respiratory Diseases Branch.
Informatics Support for Vaccine Projects Using and extending the UCSC bioinformatics infrastructure.
National Vaccine Advisory Committee November 29, 2005 Update on NIH H5N1 Vaccine Trials Linda C. Lambert Chief, Respiratory Diseases Branch Division of.
Immune Strategies for HIV Prevention
AVAC Global Advocacy for HIV Prevention AIDS Vaccines: The basics May 2015.
Creating an AIDS-Free Generation The beginning of the end of AIDS Center for Strategic & International Studies Washington, DC March 22, 2012 Thomas R.
HIV Vaccine Research & Development
HIV Vaccine Clinical Trials: In Theory and on the Ground Prof. Omu Anzala Program Director Kenya AIDS Vaccine Initiative (KAVI) Department of Medical Microbiology.
Autologous T-cell therapy based on a lentiviral vector expressing long antisense RNA targeted against HIV-1 env gene influences HIV replication and evolution.
Dr Hannah Kibuuka Makerere University Walter Reed Project Presentation at the Uganda Medical Association-Uganda Veterinary Association joint conference.
The HCV vaccine: cooperation in the shadow of the pyramids Antonella Folgori.
Prior to exposure Point of transmission After infection Male and female condoms Antiretroviral therapy (mother-to- child) Post exposure prophylaxis (PEP)
HIV Cellular Pathogenesis III
RV 144: The Thai Phase III Trial and Development of a Globally-Effective, Multi-Clade HIV Vaccine HIV Vaccine: Quo Vadis AIDS July 2010 Dr. Merlin.
The HVTN is supported by National Institute of Allergy and Infectious Diseases (NIAID). Panel 5: Current HIV Vaccine Research Clinical Research James Kublin,
On Surrogate Endpoints in HIV Vaccine Efficacy Trials Steven Self, Peter Gilbert, Michael Hudgens FHCRC/UW FDA/Industry Statistics Workshop, Sept 18-19,
Lab of Immunoregulation Berkower Lab Weiss Lab -- Angelo Spadaccini -- Russell Vassell -- Yisheng Ni -- Yong He -- Yisheng Ni -- Yong He –Hong Chen --
Food and Drug Administration
Poster # 388 CROI Feb Montreal, Canada Association of HIV-1 Co-receptor Tropism with Immunologic and Virologic Parameters in HIV-1 infected,
Washington D.C., USA, July 2012www.aids2012.org Statistical Design and Analysis for Immune Correlates Assessment: Basic Concepts and RV144 Illustration.
What Is Currently in the Pipeline & What is Ideal for an ARV-based Prevention Candidate? Carl W. Dieffenbach, Ph.D. Director, Division of AIDS, NIAID,
11 NAPWA Symposium 6 th IAS Meeting An HIV-based Lentiviral Vector Vaccine Achieves Functional Cure Post-challenge in a Subset of Vaccinated Macaques Dr.
AIDS Vaccines: the basics CindraFeuer AVAC: Global Advocacy for HIV Prevention 20 April 2010 The HIV Research Catalyst Forum Baltimore, Maryland April.
HIV Cellular Pathogenesis III Benhur Lee, M.D.. Adult v. infant (IgG v. IgA) CTL response (MHC tetramers) p24 antigenimia Ab response Viral load.
ANIMAL MODELS FOR HIV VACCINES Girish N. Vyas, Ph.D. UCSF School of Medicine, San Francisco (UCSF) A quote from the keynote Address at the January, 2008.
1 Approaches to Demonstrate Effectiveness of Vaccines for Prevention of Group B Meningococcal Disease Introduction Vaccines and Related Biological Products.
FDA/CBER Vaccines and Related biological Products Advisory Committee Meeting Discussion of Clinical Trials to Support use of Vaccines against the 2009.
VRBPAC Topic #2: Clinical Development of Influenza Vaccines for Pre-pandemic Use Joseph G. Toerner, MD, MPH VCTB/DVRPA/OVRR/CBER/FDA February 27, 2007.
Human clinical trial of DNA-MVA HIV vaccine candidate begins A Phase I study, called RV262, recently began to evaluate a combination DNA prime/MVA vector.
IAS Members Meeting July 19th 2011 Achievements and learning over the past 30 years: what do we need next? Françoise BARRÉ-SINOUSSI Regulation of Retroviral.
25 Years of HIV Vaccine Research: What have we accomplished? José Esparza MD, PhD Senior Advisor on HIV Vaccines Global Health Program The Search for an.
1 IMMUNE CORRELATES OF PROTECTION AGAINST INFLUENZA A VIRUSES IN SUPPORT OF PANDEMIC VACCINE DEVELOPMENT FDA/NIH/WHO Public Workshop, December 10-11, 2007.
VACCINES AND RELATED BIOLOGICAL PRODUCTS ADVISORY COMMITTEE ALVAC-vCP1521 plus AIDSVAX B/E CRF01_AE (Clade E) -based HIV vaccines Phase 3 Trial in Thailand.
CATEGORY: VACCINES & THERAPEUTICS HIV-1 Vaccines Shokouh Makvandi-Nejad, University of Oxford, UK HIV-1 Vaccines © The copyright for this work resides.
MHRP  The views expressed are those of the authors and should not be construed to represent the positions of the U.S. Army or the Department of Defense.
HAART Initiation Within 2 Weeks of Seroconversion Associated With Virologic and Immunologic Benefits Slideset on: Hecht FM, Wang L, Collier A, et al. A.
1 Considerations in the Pre- and Early Pandemic Use of Influenza Vaccine Jesse L. Goodman, MD, MPH Center for Biologics Evaluation and Research, VRBPAC,
Anton Sholukh IgG dose dictates outcome for passive immunization of macaques with polyclonal anti-SHIV IgG against challenge with heterologous.
HVTN 702: A pivotal phase 2b/3 multi-site, randomized, double-blind, placebo-controlled clinical trial to evaluate the safety and efficacy of ALVAC-HIV.
AVAC Global Advocacy for HIV Prevention HIV Vaccines: The basics May 2016.
04/19/ Projected effectiveness of mass HIV vaccination with multi-dose regimens to be tested in South Africa Peter Gilbert Dobromir Dimitrov Christian.
Influence of Adjuvants on HIV Env Clade C Immunity
HIV-1 Vaccines Shokouh Makvandi-Nejad, University of Oxford, UK
Earlier treatment and lower mortality in infants Initiating ART at
RV305 ADCC Update 10-February-2016 G. Ferrari.
Center for Biomedical Research
The role of non-neutraliZing antibodies in preventing HIV infection
Thumbi Ndung’u, BVM, PhD HIV Pathogenesis Programme
Non-ARV Based Interventions to Combat HIV/AIDS: New Insights and Initiatives Yves Lévy Inserm, VRI.
HIV preventative vaccines Overview of the P5 program
HIV Vaccine Trials Network
? Neutralizing Antibodies: Research pathways in 2013 and beyond
Long-term data from APPROACH study
The Rational Design of an AIDS Vaccine
Paul Stoffels, MD Vice Chairman, Chief Scientific Officer, Johnson & Johnson.
Volume 5, Issue 7, Pages e366-e378 (July 2018)
HIV-Host Interactions: Implications for Vaccine Design
Volume 24, Issue 11, Pages (November 2016)
Understanding Vaccine Partial Efficacy
Joint work with Holly Janes, Peter Gilbert
Safety and immunogenicity of a multivalent HIV vaccine comprising envelope protein with either DNA or NYVAC vectors (HVTN 096): a phase 1b, double-blind,
Presentation transcript:

23 July  RV144: Clinical Development Plans IAS 2012, Washington, DC USA The views expressed are those of the presenter and should not be construed to represent the positions of the U.S. Army or DoD Nelson L. Michael, M.D., Ph.D Colonel, Medical Corps, U.S. Army Director US Military HIV Research Program (MHRP) Walter Reed Army Institute of Research

23 July Past HIV Vaccine Concepts : AIDSVAX VaxGen Env gp120 Humoral Immunity Phase III studies in high- risk subjects in the US/Thailand Elicited type-specific Abs but not broadly reactive NAbs No efficacy 2007: STEP-PHAMBILI STUDIES Merck Ad5-Gag/Pol/Nef Cellular Immunity Phase IIb study in high-risk subjects in North/South America Elicited cellular immunity by IFN- γ ELISPOT assays No efficacy, possible increased HIV-1 acquisition 2009: RV144 Sanofi ALVAC prime, AIDSVAX gp120 boost Humoral and Cellular Immunity Phase III study in low-risk subjects in Thailand 31% reduction in HIV-1 acquisition with no viral load effect Advancing HIV vaccine candidates to efficacy trials will accelerate progress in the field, bringing us closer to an effective global vaccine. Although only three concepts have undergone clinical efficacy testing to date, each HIV vaccine efficacy trial has yielded unexpected outcomes that have transformed the HIV landscape.

23 July NEJM 361:2209 (03 Dec 09)

23 July  RV 144 demonstrated efficacy for HIV acquisition N=16, vaccine, 74 placebo HIV infected Est. VE = 31% 95% CI 1-51% (p=0.04) Rerks-Ngarm et al. (2009, NEJM) Years Probability of HIV Infection (%) Placebo Vaccine C. Modified Intention-to-Treat Analysis*

23 July What we have learned—RV 144  Protection among low incidence heterosexual Thais, VE 31.2% at 42 months  No effect on post-infection viremia or CD4 count  Relatively monophyletic circulating variants CRF01_AE  Efficacy appears to be early and non-durable  Evoked binding Ab but not measurable, primary isolate Nab— BAb appeared early and decreased by > 10 fold over 6 months  CD4+ Env responses, but not CD8 responses  Correlate/surrogate studies limited by samples and endpoints

23 July What we would want next  Extend the observation of early 60% efficacy by increasing the durability of immune responses  Additional vaccine boosts  Improved adjuvants  Improved vaccines  Elucidate correlates of risk of infection.  Adequately powered studies  Adequate sample collections  Public health implementation--establish protection in higher incidence populations (additional boosts/improved adjuvants)  Heterosexuals in sub-Saharan Africa  MSM in Africa and Asia

23 July  RV 144 correlates of risk—a teaser

23 July RV 144 Correlates Discovery Effort RV144 Steering Committee Scientific Steering Committee Product Development Advisory Group Humoral & Innate Immunity Cellular Immunity Host Genetics Animal Models Scientific Advisory Groups MHRP - DAIDS Steering Committee PA H Steering Committee ADVISORY GROUPS Clinical Development Correlates

23 July NEJM 366:1275 (05 Apr 2012)

23 July Multivariate Logistic Regression: Quantitative Variables VariableRelative riskP-valueQ-value IgA Binding to Envelope Panel IgG Avidity A244 gp ADCC AE.HIV-1 Infected CD4 Cells Tier 1 Neutralizing Antibodies IgG Binding to gp70-V1V CD4+ T Cell Intracellular Cytokines All 6 variables together in multivariate analysis, P=0.08 Only  -Env IgA and IgG gp70:V1V2 binding, p = (log reg), (Cox) 2 individual variables were significant: gp70 V1V2 inversely correlates with infection [q = 0.08] Estimated 43% reduction in infection rate (per SD) Plasma IgA directly correlates with infection [q = 0.08] Estimated 54% increase in infection rate (per SD)

23 July  Is it V1V2 or both?

23 July  Case control analysis of microarray shows trend to inverse correlation at tip of V2 and in CD4 binding site

23 July  Sieve Analysis of RV144 Breakthrough Viruses supports importance of V2 loop

23 July Sieve Analysis of V2  Comparison of viruses from HIV-1 infected vaccine versus HIV-1 infected placebo recipients  These are not transmitted/founder viruses—the mean time to last negative visit was ~ 3 months.  V2 was a major focus of analysis.  Analysis—collaboration between Dr. Morgane Rolland (MHRP), Dr. Jim Mullins (UW), SCHARP

23 July  Sequence variation in position 169 Edlefsen, SCHARP

23 July  Sequence variation in position 181 Edlefsen, SCHARP

23 July Results: Sites 169 and 181 Separately  For each site, VE significantly differs against match vs. mismatched infection  vaccine reduced infection rate 3.77 times more for 181-mm than 181-m  Positive VE for 169-matched infection and181-mismatched infection  The sieve analysis suggests that the vaccine selectively blocked acquisition with 169-matched and with 181-mismatched virus; but conferred no protection against 169-mismatched or 181-matched virus GenotypeNo. InfectionsEst. VE95% CIP-value 169m8748%18% to 66% mm23-45%-258% to 33% m88-20%-26% to 45% mm2278%35% to 93% GenotypesNo. InfectionsEst. HR / HR95% CIP-value 169mm/169 m 87/ to m/181m m 22/ to

23 July Correlates of Risk of Infection  WARNING—it is textbook (Stan Plotkin’s) knowledge that different vaccines for the same pathogen can have different correlates of risk/protection.  Will correlate of risk for ALVAC-AIDSVAX B/E in RV 144 generalize to….  These products in Thai MSM?  ALVAC-gp120 engineered for heterosexuals in Africa?  Other HIV vaccines such as DNA/Ad5 (HVTN 505 phase IIb), Ad26- MVA, etc?  We want all subsequent efficacy trials to seek correlates—now more than ever. This impacts clinical design.

23 July Collaborators Duke Bart Haynes Larry Liao Georgia Tomaras Nathan Vandergrift Garnett Kelsoe David Montefiori Thomas Kepler Marcella Sarzotti-Kelsoe Munir Alam Bill and Melinda Gates Foundation Nina Russell Francine McCutchan HVTN Peter Gilbert Nicole Frahm Julie McElrath UMDNJ Abe Pinter NYU/VA Susan Zolla-Pazner Harvard Joseph Sodroski Steve Harrison Norm Letvin IHV George Lewis Tony DeVico NIH VRC Gary Nabel Peter Kwong John Mascola Marie Pancera Jason McLellan Thai Ministry of Public Health

23 July Towards a Globally Effective HIV Vaccine

23 July MHRP’s Product Development Plan 21 REGIONAL VACCINE STRATEGY Building on the RV144 outcome and lessons learned, conduct efficacy trials of the prime-boost concept in: a)Thai MSM populations b)High-risk populations in Southern Africa BUILDING ON RV144 1 GLOBAL VACCINE STRATEGY Pursuing diverse platforms (e.g. vectors, multi- valent constructs or mosaic inserts) that build on the prime-boost concept and readily translate to multi-clade testing and a globally effective vaccine. DIVERSIFYING AND REFINING THE PORTFOLIO 2 MHRP’s vaccine development strategy emphasizes regional and global approaches.

23 July Pox-Protein Public Private Partnership (NIAID-Gates led)

23 July Planned studies are mutually reinforcing and will amplify public health impact and regional relevance. 23 May 2011 Precedent for vaccine efficacy Focus on regional public health impact Strategy for achieving potential licensure in target markets and having the broadest public health impact. Future amplification of global reach Mutually reinforcing studies strengthen and support public health benefit in target populations and the translation of the platform globally. THAILAND High Risk MSM THAILAND High Risk MSM US/EUROPE SOUTHEAST ASIA Republic of South Africa (RSA) High Risk Heterosexual Republic of South Africa (RSA) High Risk Heterosexual RV144 SOUTHERN AFRICA

23 July Timeline RV305 RV328 RV Vax (?) RV348 Bridge Study RV349 Go/No-Go

23 July Short-term Development Objectives  Characterize vaccine immune responses using samples collected  In sufficient amounts  At the right times  From systemic as well as mucosal sites  Improve magnitude and durability of vaccine- induced responses

23 July Research Strategy Three Exploratory Phase II immunogenicity trials in Thailand  Collections: serum, plasma, cells, genital fluids  Special collections: leukapheresis, gut biopsy, cervical biopsy, bone marrow aspiration (except RV305)  Broad array of humoral and cellular assays

23 July RV305 (RV144 extended boost study) =162

23 July RV306 (Intensive Immunogenicity) =460

23 July Bridging Study—from AIDSVAX/alum to delta 11/MF59  ALVAC-HIV prime as before  gp120 boost comparison:  One B and one E, both gD negative, C1 delta 11  Novartis process and MF59 adjuvant  Part A Open Label safety assessment in the U.S. for Novartis product: Wk GpN A110AAA/N A=ALVAC-HIV, N=Novartis rgp120B/E

23 July Bridging Study Part B Thailand— compare AIDSVAX/alum vs Novartis gp120/MF59 BWk GpN B1*90AAA/AVX 10PPP/P B290AAA/N 10PPP/P B390AAA/N 10PPP/P A=ALVAC-HIV, AVX=AIDSVAX B/E, N=Novartis rgp120B/E *Possibly use RV306 samples

23 July Studies: RV144i immune correlates studies RV305 protein boosting study RV306 expanded immunogenicity study Objective: Determine correlate of protection for use in future trials; optimize the regimen Partners/Funders: US Army, Thai Gov’t, NIH, sanofi pasteur, BMGF Ongoing RV144 Follow- up in Thailand Population: MSM, high-risk Products: ALVAC (sanofi) + gp120/MF59 (NVD) Objective: Confirm result & demonstrate efficacy in target population with potential for licensure Partners/Funders: US Army, Thai Gov’t, NIH, sanofi, BMGF? Thailand ph2b Population: Heterosexual, high-risk Products: ALVAC (sanofi) + gp120/MF59 (NVD) Objective: Extend result & translate vaccine to Africa, other high-risk groups Partners/Funders: NIH, HVTN, sanofi, Novartis, BMGF, RSA? Africa ph2b Population: Heterosexual, high-risk Products: DNA + NYVAC (sanofi) + gp140 (Polymun)/MF59 (NVD) vs. NYVAC (sanofi) + gp140 (Polymun)/MF59 (NVD) Objective: Extend results & accelerate evaluation of other products using adaptive trial design and first available protein Partners/Funders: NIH, HVTN, sanofi pasteur, Novartis, BMGF S. Africa ph2b Licensure Research Candidate selection ALVAC is default vector prime Proteins boosts TBD RV144 immune correlates Immune grid Cost, product availability Pox-Protein Development Plan

23 July Ad26-MVA +/- protein Barouch et al Nature 482: Feb 2012

23 July Nature 482, 89–93 (02 February 2012) % Uninfected Number of IR Challenges DNA/MVA MVA/MVA Ad26/MVA MVA/Ad26 Sham

23 July MVA/Ad26 and Ad26/MVA Regimens Lower Early Setpoint Viral Loads Following SIVmac251 Infection Log SIV RNA Days Following Infection Log SIV RNA Sham MVA/MVADNA/MVA MVA/Ad Days Following Infection Ad26/MVA x resistance to infection 4/8 : viremia blunted 1 log 3/8 : rapid virologic control 1/8 : persistently uninfected

23 July Protection Against Acquisition of IR SIVmac251 by Ad35/Ad26-SIVsmE543GagPolEnv Vaccine

23 July Ad26-MVA correlates analysis Acquisition endpoint. envelope binding antibody r=.79 p< neutralization antibody r=.50 p=.0034 ADCC r=.38 p=.034 (trend) set point viral load endpoint, Many correlates (N=27); prechallenge gag elispot count and gag elispot breadth were both correlated (r=-.50 p=.006 and r=-.64 p=.0002, respectively) with the endpoint. peak envelope binding antibody r=-.70 followed by prechallenge neutralizing antibody r=.67.

23 July Summary  RV 144 demonstrated that vaccines can provide HIV acquisition protection.  Correlates of risk of infection were discovered in RV 144.  Correlates of risk of infection in Ad26-MVA (and other) vaccines have been discovered in NHP models.  We must educate (and remind) ourselves that correlates of risk may or may not generalize.  There is great value (but at a cost) to seek correlates of infection risk in future HIV vaccine trials.  Product development and scientific rationale must communicate with each other.

23 July Acknowledgements Supported by: Collaboration for AIDS Vaccine Discovery Grant From the Bill and Melinda Gates Foundation HVTN, DAIDS, NIAID With Collaborations with the MHRP and Thai Ministry of Public Health  National Institute of Allergy and Infectious Diseases (NIAID)  National Institutes of Health (NIH)  Division of AIDS (DAIDS)  U.S. Department of Health and Human Services (HHS) Center for HIV/AIDS Vaccine Immunology (CHAVI) # U19 AI HVTN